Argenx agreed to acquire Forte Biosciences in an all-cash transaction valued at $2.2 billion. The offer of $77 per share represents a significant premium for the target company. This price reflects a 40.5% increase over Forte’s most recent closing price.
Argenx gains control of FB102, a first-in-class anti-CD122 antibody for autoimmune diseases. The deal signals continued M&A momentum within the biotechnology sector. This acquisition serves as a positive indicator for biotech-focused ETFs like XBI and ARKG. Large pharmaceutical companies are increasingly deploying capital to acquire innovative assets, potentially boosting sector-wide valuations.